{"title":"移植前赖氨酸（K）特异性甲基转移酶2A（KMT2A）部分串联重复水平可预测单倍体供体造血干细胞移植后急性髓性白血病患者的复发情况。","authors":"Dao-Xing Deng, Xiao-Hang Ma, Ze-Hua Wu, Xiao-Hui Zhang, Lan-Ping Xu, Yu Wang, Chen-Hua Yan, Huan Chen, Yu-Hong Chen, Wei Han, Feng-Rong Wang, Jing-Zhi Wang, Xiao-Jun Huang, Xiao-Su Zhao, Xiao-Dong Mo","doi":"10.1097/BS9.0000000000000207","DOIUrl":null,"url":null,"abstract":"<p><p>We aimed to identify dynamic changes of lysine (K)-specific methyltransferase 2A partial tandem duplications (<i>KMT2A</i>-PTD) before and after haploidentical donor hematopoietic stem cell transplantation (HID HSCT) and explore the prognostic value of pre-transplantation levels of <i>KMT2A</i>-PTD in acute myeloid leukemia (AML) receiving HID HSCT. Consecutive 64 AML patients with <i>KMT2A</i>-PTD positivity at diagnosis receiving HID HSCT were included in this study. Patients with <i>KMT2A</i>-PTD ≥1% before HSCT had a slower decrease of <i>KMT2A</i>-PTD after HID HSCT. Patients with <i>KMT2A</i>-PTD ≥1% before HID HSCT had a higher cumulative incidence of relapse (36.4%, 95% confidence interval [CI]: 6.3%-66.5%) at 2 years after HSCT than those with <i>KMT2A</i>-PTD <1% (7.5%, 95% CI: 0.3%-14.7%, <i>P</i> = .010). In multivariable analysis, <i>KMT2A</i>-PTD ≥1% before HID HSCT was the only independent risk factor for relapse (hazard ratio [HR]: 4.90; 95% CI: 1.22-19.59; <i>P</i> = .025). Thus, pre-transplantation levels of <i>KMT2A</i>-PTD could predict relapse in AML patients following HID HSCT.</p>","PeriodicalId":67343,"journal":{"name":"血液科学(英文)","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11427034/pdf/","citationCount":"0","resultStr":"{\"title\":\"Pre-transplantation levels of lysine (K)-specific methyltransferase 2A (<i>KMT2A</i>) partial tandem duplications can predict relapse of acute myeloid leukemia patients following haploidentical donor hematopoietic stem cell transplantation.\",\"authors\":\"Dao-Xing Deng, Xiao-Hang Ma, Ze-Hua Wu, Xiao-Hui Zhang, Lan-Ping Xu, Yu Wang, Chen-Hua Yan, Huan Chen, Yu-Hong Chen, Wei Han, Feng-Rong Wang, Jing-Zhi Wang, Xiao-Jun Huang, Xiao-Su Zhao, Xiao-Dong Mo\",\"doi\":\"10.1097/BS9.0000000000000207\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>We aimed to identify dynamic changes of lysine (K)-specific methyltransferase 2A partial tandem duplications (<i>KMT2A</i>-PTD) before and after haploidentical donor hematopoietic stem cell transplantation (HID HSCT) and explore the prognostic value of pre-transplantation levels of <i>KMT2A</i>-PTD in acute myeloid leukemia (AML) receiving HID HSCT. Consecutive 64 AML patients with <i>KMT2A</i>-PTD positivity at diagnosis receiving HID HSCT were included in this study. Patients with <i>KMT2A</i>-PTD ≥1% before HSCT had a slower decrease of <i>KMT2A</i>-PTD after HID HSCT. Patients with <i>KMT2A</i>-PTD ≥1% before HID HSCT had a higher cumulative incidence of relapse (36.4%, 95% confidence interval [CI]: 6.3%-66.5%) at 2 years after HSCT than those with <i>KMT2A</i>-PTD <1% (7.5%, 95% CI: 0.3%-14.7%, <i>P</i> = .010). In multivariable analysis, <i>KMT2A</i>-PTD ≥1% before HID HSCT was the only independent risk factor for relapse (hazard ratio [HR]: 4.90; 95% CI: 1.22-19.59; <i>P</i> = .025). Thus, pre-transplantation levels of <i>KMT2A</i>-PTD could predict relapse in AML patients following HID HSCT.</p>\",\"PeriodicalId\":67343,\"journal\":{\"name\":\"血液科学(英文)\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2024-09-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11427034/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"血液科学(英文)\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/BS9.0000000000000207\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/10/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"血液科学(英文)","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/BS9.0000000000000207","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
Pre-transplantation levels of lysine (K)-specific methyltransferase 2A (KMT2A) partial tandem duplications can predict relapse of acute myeloid leukemia patients following haploidentical donor hematopoietic stem cell transplantation.
We aimed to identify dynamic changes of lysine (K)-specific methyltransferase 2A partial tandem duplications (KMT2A-PTD) before and after haploidentical donor hematopoietic stem cell transplantation (HID HSCT) and explore the prognostic value of pre-transplantation levels of KMT2A-PTD in acute myeloid leukemia (AML) receiving HID HSCT. Consecutive 64 AML patients with KMT2A-PTD positivity at diagnosis receiving HID HSCT were included in this study. Patients with KMT2A-PTD ≥1% before HSCT had a slower decrease of KMT2A-PTD after HID HSCT. Patients with KMT2A-PTD ≥1% before HID HSCT had a higher cumulative incidence of relapse (36.4%, 95% confidence interval [CI]: 6.3%-66.5%) at 2 years after HSCT than those with KMT2A-PTD <1% (7.5%, 95% CI: 0.3%-14.7%, P = .010). In multivariable analysis, KMT2A-PTD ≥1% before HID HSCT was the only independent risk factor for relapse (hazard ratio [HR]: 4.90; 95% CI: 1.22-19.59; P = .025). Thus, pre-transplantation levels of KMT2A-PTD could predict relapse in AML patients following HID HSCT.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
